Shengwei Hu

Prof. Dr. Shengwei Hu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2026 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
HYHaihua Yang
Haihua Yang
PLPeipei Li
Peipei Li
JJJiao Jiao
Jiao Jiao
TLTao Li
Tao Li
YLYuhui Li
Yuhui Li
PWpeng wu
peng wu

23 April 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
JWJinyu Wang
Jinyu Wang
JBJinlong Bai
Jinlong Bai
YLYuhui Li
Yuhui Li
RHRuirui Hu
Ruirui Hu
HYHaihua Yang
Haihua Yang
WNWei Ni
Wei Ni
Carbapenem-resistant Acinetobacter baumannii (CRAB) is classified as a critical priority pathogen by the World Health Organization, and new therapeutic alternatives are urgently needed. In this study, we performed genomic mining of 27,531 A. baumannii genomes and identified 5144 prophage-derived endolysin candidates. Four highly prevalent candidates (E1–E4) were recombinantly expressed and functionally evaluated against A. baumannii. Among them, E1 exhibited the strongest bactericidal activity against reference strains ATCC 19606 and CMCC 25001, with a minimum inhibitory concentration in the micromolar range. E1 effectively disrupted preformed biofilms (>60% reduction) and remained stable under a broad range of temperatures (4–60 °C), pH values (6–8), and NaCl concentrations (up to 500 mM). Structural analysis indicated that E1 adopts a canonical lysozyme-like fold with key residues for peptidoglycan binding, and its lytic activity in vitro relied on 1 mM EDTA-mediated outer membrane permeabilization. In a murine peritoneal infection model, combination therapy with E1 and meropenem (each at 1 × MIC) significantly increased the survival rate to 66.7% and reduced bacterial loads in blood and multiple organs. This study demonstrates that prophage-derived endolysin E1 acts synergistically with meropenem against A. baumannii, supporting E1 as a promising candidate for developing combination therapies against CRAB.